Urine Immunofixation Electrophoresis Quantitative
- Sample Type
- Urine (24h)
- Fasting
- No
- Unit
- mg/24h
Function
Urine Immunofixation Electrophoresis (IFE) is a sensitive laboratory technique used to identify specific types of proteins called immunoglobulins (antibodies) in the urine. While standard protein tests might show total protein, IFE 'fixes' these proteins using specific antibodies to see if there is a 'monoclonal' (identical) population, which suggests a single clone of plasma cells is overproducing them.
Why it is Ordered
This test is a critical diagnostic tool when a physician suspects Multiple Myeloma, Waldenström's macroglobulinemia, or Amyloidosis. It is specifically used to detect Bence-Jones proteins (free light chains) in the urine, which may not show up on a standard blood protein electrophoresis because they are small enough to be filtered rapidly by the kidneys.
Associated Conditions
- Multiple Myeloma: A cancer of the plasma cells in the bone marrow.
- MGUS: Monoclonal Gammopathy of Undetermined Significance.
- AL Amyloidosis: A condition where abnormal proteins build up in organs.
- B-cell Lymphomas: Certain lymphomas can produce monoclonal proteins.
Check Your Result
Check Your Result
Enter your lab result to see where you stand compared to the standard reference range.
Why Context Matters
The interpretation of IFE is highly specialized and relies on the visual identification of 'bands' by a pathologist. A 24-hour urine collection is required for quantitative accuracy; if the patient fails to collect all urine within that period, the results will be falsely low. Furthermore, the presence of a 'monoclonal band' does not always mean cancer (as in MGUS), necessitating a second opinion from a hematologist to avoid unnecessary anxiety.
Lab ranges are statistical averages, not biological laws. "Normal" for a 20-year-old male isn't normal for a 60-year-old female.
Clinical References
Source-of-truth databases and clinical guidelines for Urine Immunofixation Electrophoresis Quantitative:
Official Sources
- Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology - PubMedpubmed.ncbi.nlm.nih.gov
- NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025 - PubMedpubmed.ncbi.nlm.nih.gov
Research & Guidelines
Related Indicators
Medically Reviewed by Dr. Binoy Babu, MBBS
Board Certified Doctor • 10+ Years Clinical Experience
Dr. Babu is a practicing physician dedicated to empowering patients with clear, actionable medical information. He founded 2opi to bridge the gap between complex lab reports and patient understanding, ensuring everyone has access to a reliable second opinion.
Get Notified When Dr. Babu Is Available